Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
Txylo.com/10101443
Trending...
- Orbital Energy Group, Inc. Announces Closing Of $35 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- City Streaming TV, a Streaming Television Inc Network Launches, bringing Community and Faith Leaders into local TV's, At No Cost
- Wright's Media Announces New Collaboration with Wirecutter, A New York Times Company
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that management will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, December 1-3, 2020. Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, will provide a pre-recorded investor presentation and will be available for virtual one-on-one investor meetings during the conference.
Meetings may be requested exclusively through Piper Sandler. The pre-recorded company presentation will be available via the Piper Sandler conference site from November 23 to December 3 and on the Castle Biosciences website at https://ir.castlebiosciences.com/investors.
About Castle Biosciences
More on Txylo.com
Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq), cutaneous squamous cell carcinoma (DecisionDx®-SCC), suspicious pigmented lesions (DecisionDx® DiffDx™-Melanoma) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq). For more information about Castle's gene expression profile tests, visit www.CastleTestInfo.com. Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit www.CastleBiosciences.com.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq and are trademarks of Castle Biosciences, Inc.
Meetings may be requested exclusively through Piper Sandler. The pre-recorded company presentation will be available via the Piper Sandler conference site from November 23 to December 3 and on the Castle Biosciences website at https://ir.castlebiosciences.com/investors.
About Castle Biosciences
More on Txylo.com
- Port Houston Commission Meeting January 26
- CPS Energy Seeks Applicants For Rate Advisory Committee
- San Antonio: Councilwoman Jada Andrews-Sullivan issues statement on violence in District 2
- Geospace Technologies Reports First Quarter 2021 Results and Conference Call Schedule
- Texas nut company brings healthy nut mixes, candies to the health conscious
Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq), cutaneous squamous cell carcinoma (DecisionDx®-SCC), suspicious pigmented lesions (DecisionDx® DiffDx™-Melanoma) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq). For more information about Castle's gene expression profile tests, visit www.CastleTestInfo.com. Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit www.CastleBiosciences.com.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq and are trademarks of Castle Biosciences, Inc.
Filed Under: Business
0 Comments
Latest on Txylo.com
- MoneyGram Expands Real-Time Digital P2P Payments with Visa Direct through New Checkout.com Partnership
- Kaizen Finance Launches Staking to Foster the Widespread Adoption of DeFi
- Ismail Sirdah Describes the Best Practices for Holding Corporate Events
- MDAdvantage Appoints Pete Cammarano to Board of Directors
- CEO Coaching International Congratulates Client Orion Energy on Successful Capital Partnerships
- expEDIum Direct Pay®, seamless online payment added to iTech's expEDIum Medical Billing®
- Hilcorp Energy I, L.P. Announces Early Results of Dual Cash Tender Offers and Amendment of Offer for 2025 Notes
- Idera, Inc. Announces Investment from Partners Group
- Sungrow Supplies a 100 MW Energy Storage Project in Texas
- GPD Companies, Inc. Announces Successful Consent Solicitation
- COMSovereign Holding Corp. Announces Nasdaq Listing and Pricing of $16.0 Million Public Offering
- San Antonio: Councilwoman Sandoval Applauds Health Priorities in Newly-Minted Federal Legislative Agenda
- San Antonio: A Statement from District 1 Councilman Roberto Treviño on Emergency Rental Assistance Additional Funding
- Brinks Home Security Announces Long-Term Contract with Largest Dealer, Skyline Security
- San Antonio: Councilman Pelaez Praises Passage of 117th Federal Legislative Program, Emphasizes Impact of Advocacy Efforts
- China Refuses to Accept Service of Berman Law Group's Coronavirus Class Action Complaint
- Texas Instruments board declares first quarter 2021 quarterly dividend
- Love & Sip Valentine Brunch with Celebrity The Comedian, Tomea, Grammy Saxophonist Jason Davis, Gospel Contemporary Duo, Only God Ministries
- Corey Edward and FyreSyde Publishing Announce the Release of Friday Nightmares
- Rustic Deco Launches B2B Wholesale Furniture Website